Ironman580
Member
There is somthing severely wrong with that - don’t even think of pinning that
MESO-Rx
Anabolic Steroids
MESO-Rx Sponsor Pharmacom Labs officials and our Basicstero.com store
- Thread starter PHL Official
- Start date
fearlessbee7516
New Member
Do you have any statistics on seizure rates w/ stealth shipping?
Active hyperlinks to ecommerce-enabled website domains that sell pharmaceuticals are prohibited.
Nowadays our only direct store is [EDIT: ACTIVE HYPERLINK IN VIOLATION OF RULES REMOVED]
We have already restocked the domestic warehouse few days ago, specifically with any esters of Test and some high-quality products.
Of course, but its a confidential information of our company.
RThoads
Subscriber
All warehouses are now listed on one site/page.
Simply make the purchase from the warehouse of your choice.
W3 is the US domestic warehouse.
The correct for Basicstero's website/store is:
basicstero.ws
Just make sure you are using the correct address.
Here is my correct personal referral link below in the "code" box below:
Code:
https://basicstero.ws/login?ref=6240Please note, this is my own personal referral link (so I get some store credit for my efforts if a new customer makes an account using my specific link); but it is no problem if one chooses to use or not use my referral link (it not a requirement at all to give me credit). I try my best to help everyone regardless of if you use my referral or not.
Important: This source does not take orders via email.
I have recently been made aware of a potential scammer sending emails to people pretending to by Pharmacom and offer "bulk pricing."
If anyone tries to get you to place a new order via email, it is a scam.
BEWARE OF SCAMMERS! ALL ORDERS SHOULD ONLY BE PLACED AND PROCESSED THROUGH THE CHECKOUT IN THE OFFICIAL STORE!
kinistone
Banned
WTF is going on with stoppers lately. Here and that other source thread.
kinistone
Banned
Ive never seen that before. So this pic is before you pulled any liquid out of the vial?
RThoads
Subscriber
It is nothing new; I have seen this many times going back over the years.
I made a post a while back where I collected previous examples and replies.
Please see my post linked below for more info:
Stopper Divot Info/Replies Compilation
RThoads
Subscriber
NEW PRODUCT: Pharmacom Testosterone Undecanoate
Now available to purchase at (link in "code" box below):
Code:
https://basicstero.ws/testosterones/pharmatest-u-250Testosterone undecanoate (primarily marketed and known from the trade-name “Nebido”), is a very slow-acting ester of testosterone. This is the active drug that is used in Andriol, but in that case it is part of an oral medication, not an injectable. Nebido is being marketed as a replacement for established injectable testosterone products like Delatestryl®, Depo-Testosterone®, and Sustanon®, which are actually much faster acting in comparison. It is designed to offer a much less frequent injection schedule, and, therefore, much greater comfort for the patient. Nebido is a drug developed under a similar focus as testosterone buciclate, which is another very slow-acting injectable ester of testosterone.
History:
Nebido® was developed by international giant Schering AG, Germany (now Bayer). It first surfaced as a prescription drug in Finland and Germany in October and November of 2004, respectively. Within a year it had been approved for sale throughout Europe. Schering/Bayer has since also brought this product to Mexico, Brazil, Argentina, South Africa, Colombia, Korea, Venezuela, and various countries in Eastern Europe (86 countries in total). In July 2005, the U.S. pharmaceuticals firm Indevus purchased the rights to market Nebido under the Aveed trade name. The FDA has since held up U.S. approval of the drug, however, focusing on a small number of adverse reports in Germany. These specifically involve post-injection anaphylactic reactions and pulmonary oil microembolism. Most of these reactions are likely not due to a problem with the drug itself, but incorrect administration of the high-volume injection. Future approval in the U.S. is expected, but unclear.
Nebido® was described by Schering as being the, “first long-acting injection for the treatment of male hypogonadism.” This may be a matter of perspective, as other slow-acting esters do exist. Schering, however, is taking the lead to market in most regions. The applications for Nebido® are extremely narrow, being approved for use in men as a long-term treatment option for low androgen levels only. It is not labeled for use in women, or in males for other uses. Given the growing acceptance of androgen replacement therapy, and the comfort advantage that Nebido® seems to offer male hormone replacement therapy patients (esters like enanthate and cypionate generally require between 13 and 26 injections per year), it may very well become a dominant testosterone product in the years to come, especially with the marketing support of a pharmaceutical giant like Bayer.
Structural Characteristics:
Testosterone undecanoate is a modified form of testosterone, where a carboxylic acid ester (undecanoic acid) has been attached to the 17-beta hydroxyl group. Esterified forms of testosterone are less polar than free testosterone, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Nebido® is designed to maintain physiological levels of testosterone for up to 14 weeks after injection.
Side Effects (Estrogenic):
Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.
Estrogenic side effects will occur in a dose-dependent manner, with higher doses (above normal therapeutic levels) of testosterone more likely to require the concurrent use of an anti-estrogen or aromatase inhibitor. Since water retention and loss of muscle definition are common with higher doses of testosterone, this drug is usually considered a poor choice for dieting or cutting phases of training. Its moderate estrogenicity makes it more ideal for bulking phases, where the added water retention will support raw strength and muscle size, and help foster a stronger anabolic environment.
Side Effects (Androgenic):
Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Those concerned about hair loss may find a more comfortable option in nandrolone decanoate, which is a comparably less androgenic steroid. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependent on its reduction to dihydrotestosterone (DHT). The 5-alpha reductase enzyme is responsible for this metabolism of testosterone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.
Side Effects (Hepatotoxicity):
Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2,800 mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependent on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
Testosterone tends to have a much less dramatic impact on cardiovascular risk factors than synthetic steroids. This is due in part to its openness to metabolism by the liver, which allows it to have less effect on the hepatic management of cholesterol. The aromatization of testosterone to estradiol also helps to mitigate the negative effects of androgens on serum lipids. In one study, 280 mg per week of testosterone ester (enanthate) had a slight but not statistically significant effect on HDL cholesterol after 12 weeks, but when taken with an aromatase inhibitor a strong (25%) decrease was seen. Studies using 300 mg of testosterone ester (enanthate) per week for twenty weeks without an aromatase inhibitor demonstrated only a 13% decrease in HDL cholesterol, while at 600 mg the reduction reached 21%. The negative impact of aromatase inhibition should be taken into consideration before such drug is added to testosterone therapy.
Due to the positive influence of estrogen on serum lipids, tamoxifen citrate or clomiphene citrate are preferred to aromatase inhibitors for those concerned with cardiovascular health, as they offer a partial estrogenic effect in the liver. This allows them to potentially improve lipid profiles and offset some of the negative effects of androgens. With doses of 600 mg or less per week, the impact on lipid profile tends to be noticeable but not dramatic, making an anti-estrogen (for cardioprotective purposes) perhaps unnecessary. Doses of 600 mg or less per week have also failed to produce statistically significant changes in LDL/VLDL cholesterol, triglycerides, apolipoprotein B/C-III, C-reactive protein, and insulin sensitivity, all indicating a relatively weak impact on cardiovascular risk factors. When used in moderate doses, injectable testosterone esters are usually considered to be the safest of all anabolic/androgenic steroids.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Administration (General):
Due to the large injection volume, prescribing guidelines recommend that each injection be given slowly, taking approximately 60 seconds to administer the full dose. Nebido® should always be injected deep in large muscle.
Availability:
Testosterone undecanoate injection continues to increase in prominence as a pharmaceutical product. It is presently approved for sale in 86 countries worldwide. In reviewing some of the more popular products and changes on the global pharmaceutical market, we have made the following observations. Nebido gained approval for Europe-wide sales in 2005. The product has since been distributed throughout Europe, and is widely available in this region. Indevus, a subsidiary of Endo Pharmaceuticals, has continued to push for FDA approval of Aveed in the United States.
*(credit: “ANABOLICS” 10th ed. by William Llewellyn)
Rottendog
Member
Is there really a demand for test with an ultra-long ester? Seems like the blood level lag time at either start or stop or adjustment would be a gigantic PITA.
Take some Tren and that stopper will become much more appealing.
RThoads
Subscriber
It is great for TRT/cruise.
I think many men are now of TRT and/or blast & cruise.
With cruising there is no start and stop time -- no PCT or coming completely off ever again -- it is a lifetime commitment to always be on hormone therapy.
It this case, it is nice to get a break from pinning so often.
A very long ester allows longer time between administration of dosage.
Rottendog
Member
Yeah, I can see the appeal for the needle averse. How long does it take to reach stable blood levels with an ester that slow? How long does it take to clear once you stop it or reduce your dosage due to sides? I'm not saying it's bullshit, but it just seems like it might be hard to control in the opposite way from test p or TNE.
RThoads
Subscriber
"Nebido" is the name of legal prescription of this compound; you may do a search for Nebido and find more info and research.
Also, my post quoted below has the information from “ANABOLICS” 10th ed., by William Llewellyn, about this compound.
This is the information I have so far; I have not yet used this compound personally to have any first-hand experience.
Now available to purchase at (link in "code" box below):
Testosterone-Undecanoate Information*:Code:https://basicstero.ws/testosterones/pharmatest-u-250
Testosterone undecanoate (primarily marketed and known from the trade-name “Nebido”), is a very slow-acting ester of testosterone. This is the active drug that is used in Andriol, but in that case it is part of an oral medication, not an injectable. Nebido is being marketed as a replacement for established injectable testosterone products like Delatestryl®, Depo-Testosterone®, and Sustanon®, which are actually much faster acting in comparison. It is designed to offer a much less frequent injection schedule, and, therefore, much greater comfort for the patient. Nebido is a drug developed under a similar focus as testosterone buciclate, which is another very slow-acting injectable ester of testosterone.
History:
Nebido® was developed by international giant Schering AG, Germany (now Bayer). It first surfaced as a prescription drug in Finland and Germany in October and November of 2004, respectively. Within a year it had been approved for sale throughout Europe. Schering/Bayer has since also brought this product to Mexico, Brazil, Argentina, South Africa, Colombia, Korea, Venezuela, and various countries in Eastern Europe (86 countries in total). In July 2005, the U.S. pharmaceuticals firm Indevus purchased the rights to market Nebido under the Aveed trade name. The FDA has since held up U.S. approval of the drug, however, focusing on a small number of adverse reports in Germany. These specifically involve post-injection anaphylactic reactions and pulmonary oil microembolism. Most of these reactions are likely not due to a problem with the drug itself, but incorrect administration of the high-volume injection. Future approval in the U.S. is expected, but unclear.
Nebido® was described by Schering as being the, “first long-acting injection for the treatment of male hypogonadism.” This may be a matter of perspective, as other slow-acting esters do exist. Schering, however, is taking the lead to market in most regions. The applications for Nebido® are extremely narrow, being approved for use in men as a long-term treatment option for low androgen levels only. It is not labeled for use in women, or in males for other uses. Given the growing acceptance of androgen replacement therapy, and the comfort advantage that Nebido® seems to offer male hormone replacement therapy patients (esters like enanthate and cypionate generally require between 13 and 26 injections per year), it may very well become a dominant testosterone product in the years to come, especially with the marketing support of a pharmaceutical giant like Bayer.
Structural Characteristics:
Testosterone undecanoate is a modified form of testosterone, where a carboxylic acid ester (undecanoic acid) has been attached to the 17-beta hydroxyl group. Esterified forms of testosterone are less polar than free testosterone, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Nebido® is designed to maintain physiological levels of testosterone for up to 14 weeks after injection.
Side Effects (Estrogenic):
Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.
Estrogenic side effects will occur in a dose-dependent manner, with higher doses (above normal therapeutic levels) of testosterone more likely to require the concurrent use of an anti-estrogen or aromatase inhibitor. Since water retention and loss of muscle definition are common with higher doses of testosterone, this drug is usually considered a poor choice for dieting or cutting phases of training. Its moderate estrogenicity makes it more ideal for bulking phases, where the added water retention will support raw strength and muscle size, and help foster a stronger anabolic environment.
Side Effects (Androgenic):
Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Those concerned about hair loss may find a more comfortable option in nandrolone decanoate, which is a comparably less androgenic steroid. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependent on its reduction to dihydrotestosterone (DHT). The 5-alpha reductase enzyme is responsible for this metabolism of testosterone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.
Side Effects (Hepatotoxicity):
Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2,800 mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependent on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
Testosterone tends to have a much less dramatic impact on cardiovascular risk factors than synthetic steroids. This is due in part to its openness to metabolism by the liver, which allows it to have less effect on the hepatic management of cholesterol. The aromatization of testosterone to estradiol also helps to mitigate the negative effects of androgens on serum lipids. In one study, 280 mg per week of testosterone ester (enanthate) had a slight but not statistically significant effect on HDL cholesterol after 12 weeks, but when taken with an aromatase inhibitor a strong (25%) decrease was seen. Studies using 300 mg of testosterone ester (enanthate) per week for twenty weeks without an aromatase inhibitor demonstrated only a 13% decrease in HDL cholesterol, while at 600 mg the reduction reached 21%. The negative impact of aromatase inhibition should be taken into consideration before such drug is added to testosterone therapy.
Due to the positive influence of estrogen on serum lipids, tamoxifen citrate or clomiphene citrate are preferred to aromatase inhibitors for those concerned with cardiovascular health, as they offer a partial estrogenic effect in the liver. This allows them to potentially improve lipid profiles and offset some of the negative effects of androgens. With doses of 600 mg or less per week, the impact on lipid profile tends to be noticeable but not dramatic, making an anti-estrogen (for cardioprotective purposes) perhaps unnecessary. Doses of 600 mg or less per week have also failed to produce statistically significant changes in LDL/VLDL cholesterol, triglycerides, apolipoprotein B/C-III, C-reactive protein, and insulin sensitivity, all indicating a relatively weak impact on cardiovascular risk factors. When used in moderate doses, injectable testosterone esters are usually considered to be the safest of all anabolic/androgenic steroids.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Administration (General):
Due to the large injection volume, prescribing guidelines recommend that each injection be given slowly, taking approximately 60 seconds to administer the full dose. Nebido® should always be injected deep in large muscle.
Availability:
Testosterone undecanoate injection continues to increase in prominence as a pharmaceutical product. It is presently approved for sale in 86 countries worldwide. In reviewing some of the more popular products and changes on the global pharmaceutical market, we have made the following observations. Nebido gained approval for Europe-wide sales in 2005. The product has since been distributed throughout Europe, and is widely available in this region. Indevus, a subsidiary of Endo Pharmaceuticals, has continued to push for FDA approval of Aveed in the United States.
*(credit: “ANABOLICS” 10th ed. by William Llewellyn)
Metro Boomin
Banned
The shitshow continues..You know how many ppl were waiting for a primo200 restock for almost a year now?I was holding back on all big orders this year because of the issues going on and no primo200.Didn't you say on page 1400 that ETA will be beginning of October?And now you cancelled production of alot of ppls favorite product?Why?Are you telling me you couldn't get enought raws for a batch?Or is the profit/expense ratio not worth it anymore with all custom seizures going on lately?
Metro Boomin
Banned
Test u has neither a place in TRT nor in Sports. Its just a way for bayer to make a shitton of money with the patent.The only purpose might be if you go on a long ass vacation/business trip ,so you wont crash your test levels.
RThoads
Subscriber
I am interested in it because it appears that I would be able to pin only once a week and have stable levels, maybe even once every other week and still be good to go. At my age and so may things pulling on my schedule (work, family, travel etc), being stuck on TRT for life is a big commitment so anything that may allow less frequent pins would be appreciated.
My priority is stable levels so I do twice a week with my CYP. Many of my peers do it once a week cyp or longer (some doctors tell them once every other week -- that is a no way for me).
But with the long ester Test-U, I would be comfortable trying once a week.
All just ideas though; like I said, I have never actually tried it.
RThoads
Subscriber
I understand your disappointment.
Many were waiting for this to return, including myself (the Primo200 and Test are all I have used for for a few years).
Unfortunately, I do not have any details and only see the same announcement you have read here.
I am sorry to hear, but it is beyond my control.
All I can do is ask @Pharmacom Labs if he can offer more details or info than that to which I have access.
